This is a single armed and open labelled trial in patients with recurrent HBV related HCC after liver transplantation. For patients who successfully match TCR histocompatibility locus antigen (HLA) restriction, escalating doses of HBV/TCR expressing autologous T cells will be infused. Tests will be done to confirmed safety and efficacy during treatment, followed by one month immediate observation period for safety and a long-term follow up period up to five years for efficacy.